BWXT Medical, TRIUMF Agree To Manufacture High Purity Ac-225 Based Products

  • BWX Technologies Inc BWXT subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have established a licensing and services agreement.
  • The agreement strengthens their existing partnership for the production of medical isotopes. It enables BWXT Medical to manufacture high purity Actinium-225 (Ac-225) based products for pharmaceutical companies as it continues to build on its medical isotope production operations on the TRIUMF site.
  • Leveraging existing infrastructure, TRIUMF will irradiate thorium-232 targets for BWXT Medical. BWXT Medical processes and produces high purity Ac-225, sometimes called non-carrier-added Ac-225, for commercial sale, strengthening BWXT Medical’s position as a leading global manufacturer and supplier of critical medical isotopes and radiopharmaceuticals.
  • “We anticipate being the first company to produce non-Russian sourced high purity Ac-225 at semi-scale, starting this summer (2022). Our intention is to partner with a small number of leading pharmaceutical companies, initially supplying the isotope, and with line-of-sight to a deeper relationship including contract development and manufacturing of the finished products,” commented Martyn Coombs, president, BWXT Medical.
  • Price Action: BWXT shares are trading lower by 1.77% at $52.16 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsContractsBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!